FDA Approves First Gene Therapy for Treatment of Aromatic L …
2 days ago · The efficacy of Kebilidi was demonstrated based on gross motor function improvement in 8 of 12 treated patients, which has not been reported in untreated patients with the severe presentation of ...
Kebilidi, a Gene Therapy for AADC Deficiency, Gets Accelerated
1 day ago · Kebilidi is a one-time, recombinant adeno-associated virus-based gene therapy administered through intraputaminal infusion. ... News release. PTC Therapeutics. November 13, 2024.
FDA Approves Kebilidi - Drugs.com
Kebilidi is an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This indication is approved under accelerated approval based on change from baseline in gross motor milestone achievement at 48 weeks post-treatment.
PTC Therapeutics Wins First FDA Approval for a Gene Therapy …
2 days ago · The PTC Therapeutics gene therapy, Kebilidi, treats an enzyme deficiency that affects the body’s ability to produce dopamine, a neurotransmitter important for motor control. FDA approval for the ...
KEBILIDI | FDA - U.S. Food and Drug Administration
2 days ago · (1, 14) KEBILIDI is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L amino acid decarboxylase (AADC) deficiency.
FDA grants accelerated approval for PTC’s AADC deficiency gene …
1 day ago · The FDA's accelerated approval is based on the safety and clinical efficacy findings from the ongoing PTC-AADC-GT-002 global clinical trial. KEBILIDI works by replacing the defective gene and is ...
PTC Therapeutics Announces FDA Approval of AADC
3 days ago · Patients should be monitored for procedure related adverse events with KEBILIDI administration. Dyskinesia: Dyskinesia was reported after administration of KEBILIDI. All events were reported ...
FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC …
1 day ago · Kebilidi is the first FDA-approved gene therapy for the deficiency. PTC shares gained around 8.5 percent in the extended trading on the Nasdaq on Thursday, at $45.97. AADC deficiency is a rare genetic disorder that affects the production of some neurotransmitters, which are chemical messengers that allow cells in the body's nervous system to ...
PTC wins US approval of gene therapy for fatal enzyme disorder
1 day ago · PTC Therapeutics on Wednesday won Food and Drug Adminitration approval for Kebilidi, the first gene therapy cleared in the U.S. for direct administration to the brain. The treatment is designed for patients with aromatic L-amino acid decarboxylase, or AADC, deficiency, a condition that affects the way neurons transmit information to other cells.
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets ...
2 days ago · The FDA on Wednesday signed off on PTC Therapeutics’ gene therapy eladocagene exuparvovec-tneq for the treatment of aromatic L-amino acid decarboxylase deficiency. The treatment will be marketed under the brand name Kebilidi. With only around 350 cases reported in the literature, aromatic L-amino acid decarboxylase (AADC) deficiency is an ultrarare genetic disease characterized by severe ...
- Some results have been removed